AstraZeneca to switch entire fleet to electric vehicles by 2030
pharmafile | July 17, 2019 | News story | Research and Development | AstraZeneca, EV100, electric vehicles, environmentalism, pharma, renewables
AstraZeneca has revealed plans to use only electric vehicles by 2030.
In joining the EV100 group, AstraZeneca will transfer the entirety of its 16,000 strong fleet to electric vehicles.
The move is set to save 80,000 metric tonnes of CO2 each year. It is hoped the switch to electric will reduce the negative health impact of air pollution across the globe.
In joining EV100, whose members include BT, Unilever and the Bank of America, AstraZeneca will become the first pharmaceutical company to pledge its commitment to the group.
Helen Clarkson, CEO of The Climate Group, commented: “When a pharmaceutical company says we need to go electric to help everyone breathe clean air, every business with a fleet needs to listen.
“This is great example of a company addressing the global climate and air pollution crisis. As the first global healthcare company to flip its fleet through EV100, and the 50th large business to do so, AstraZeneca is setting a new benchmark in the drive to electric vehicles.”
Katarina Ageborg, EVP, Sustainability and Chief Compliance Officer, AstraZeneca, said: “Recognising the link between a healthy environment and human health, we believe that by investing in electric vehicles and emissions-reduction initiatives, we can help reduce the burden of respiratory diseases and other air pollution-related conditions. Environmental stewardship will prevent disease as well as protect the planet for future generations.
“Sustainable business is about addressing the impact of our activities on both the planet and on people’s health and this needs to be a joint effort. We should all work together in partnership on climate action.”
AstraZeneca is currently part of the RE100 group which sees companies pledge their commitment to sourcing energy only from renewables. The Anglo-Swedish multinational has thus pledged to use only renewable energy by 2020 in Europe and by 2025 in the United States.
Louis Goss
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …
